Table 2.
Oral Membrane Phospholipid Supplementation and Fatigue in Chronically Ill Patientsa
| Participants/Patients | n | Avg Age | Avg Time on LRT | PFS Fatigue Reduction (%) | Reference |
|---|---|---|---|---|---|
| Chronic fatigue | 34 | 50.3 | 8 wk | 40.5c | Ellithorpe et al117 |
| Aging, chronic fatigue | 20 | 68.9 | 12 wk | 35.5b | Agadjanyan et al55 |
| Chronic fatigue syndrome (and/or fibromyalgia syndrome) | 15 | 44.8 | 8 wk | 43.1b | Nicolson & Ellithorpe116 |
| Aging, fatigue | 67 | 57.3 | 1 wk | 36.8b | Nicolson et al118 |
| Chronic illnesses | 58 | 55.0 | 8 wk | 30.7b | Nicolson et al119 |
Abbreviations: Avg = average; LRT = lipid replacement therapy; PFS = Piper Fatigue Scale.
a
Modified from Nicolson and Settineri.54
b
P < .001 compared to no supplement.
c
P < .0001 compared to no supplement.